# Taro Inaba

> Taro Inaba is a Series A investor at Remiges Ventures backing Biotechnology and Life Science. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Remiges Ventures](https://shizune.co/investors/profile/remiges-ventures)
- Location: Tokyo, Japan
- Total investments: 4
- Last investment: Jun 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/taro-inaba-33739a5

Taro Inaba is a Founder and Managing Partner at Remiges Ventures. He Attended European University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Life Science | 2 | 50% |
| Medical | 1 | 25% |
| Health Care | 1 | 25% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 50% |
| Japan | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LUCA Science | LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $29.2M | Series B | Jun 06, 2022 |  |
| Capacity Bio | Capacity Bio is a therapeutics company that is focused on mitophagy. Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondrial quality control in disease. |  | Seed | Jan 01, 2022 |  |
| LUCA Science | LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $9.8M | Series A | Sep 01, 2020 |  |
| Tranquis Therapeutics | Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratoryof Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease. | $30M | Series A | Jul 09, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 3 deals together
- [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 3 deals together
- [Nippon Venture Capital](https://shizune.co/investors/profile/nippon-venture-capital) — VC Fund, 3 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- [Asahi Kasei Pharma](https://shizune.co/investors/profile/asahi-kasei-pharma) — VC Fund, 1 deal together
- [Axil Capital](https://shizune.co/investors/profile/axil-capital) — VC Fund, 1 deal together

## About Remiges Ventures

VC Fund · Cambridge, United States

Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.

2 contacts available at Remiges Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Taro Inaba | Founder and Managing Partner | https://shizune.co/investors/profile/taro-inaba |
| Takahide Koda | Partner | https://shizune.co/investors/profile/takahide-koda |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Taro Inaba invest in?

Taro Inaba invests primarily in Biotechnology, Life Science and Medical startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Taro Inaba last invest?

The most recent investment recorded for Taro Inaba closed in Jun 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co